Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,145 full-time employees. The company went IPO on 2007-04-02. The firm operates through one segment: Pharmaceuticals. The firm manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.